InspireMD (NSPR) Scheduled to Post Earnings on Tuesday

InspireMD (NYSE:NSPR) will be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect InspireMD to post earnings of ($0.20) per share for the quarter.

InspireMD (NYSE:NSPR) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $1.74 million. During the same quarter last year, the firm posted ($0.24) earnings per share. On average, analysts expect InspireMD to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InspireMD Stock Performance

Shares of NYSE:NSPR traded down $0.01 during trading hours on Tuesday, hitting $2.46. 13,316 shares of the company’s stock traded hands, compared to its average volume of 23,933. The company’s fifty day simple moving average is $2.65 and its two-hundred day simple moving average is $2.56. The company has a market cap of $61.33 million, a price-to-earnings ratio of -3.34 and a beta of 0.93. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.48.

Analyst Ratings Changes

NSPR has been the topic of several recent research reports. Piper Sandler restated an “overweight” rating and issued a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th. StockNews.com assumed coverage on InspireMD in a research report on Saturday. They set a “sell” rating on the stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.